Trials / Conditions / Lymphoma, Malignant

Lymphoma, Malignant

17 registered clinical trials studyying Lymphoma, Malignant.

Status	Trial	Sponsor	Phase
Unknown	Efficacy of Patient Management for Lymphoma Diagnosed at Nimes University Hospital From 1999 to 2018. DVR-Lym- NCT04947618	Centre Hospitalier Universitaire de Nīmes	—
Withdrawn	A Study to Evaluate the Effect of Food on the Pharmacokinetics (PK) of TAK-659 in Participants With Advanced S NCT03359733	Calithera Biosciences, Inc	Phase 1
Completed	Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG NCT02916979	Dartmouth-Hitchcock Medical Center	Phase 1
Unknown	a Clinical Research of Sequential CAR-T Bridging HSCT in the Treatment of Relapse/Refractory B-cell Malignanci NCT02846584	Southwest Hospital, China	Phase 2
Active Not Recruiting	DS-3201b in Participants With Lymphomas NCT02732275	Daiichi Sankyo Co., Ltd.	Phase 1
Completed	Open-Label, Non Randomized Phase 2 Study With Safety Run-In NCT02249429	PIQUR Therapeutics AG	Phase 2
Terminated	A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors NCT02440685	Asana BioSciences	Phase 1 / Phase 2
Unknown	Clinic Study of 18F-Al-NOTA-PRGD2 in Cancer Diagnostics NCT02441972	Wuxi No. 4 People's Hospital	Phase 1
Completed	A Study of Enzastaurin in Chinese Patients With Advanced and/or Metastatic Solid Tumors or Lymphoma NCT01432951	Eli Lilly and Company	Phase 1
Completed	A Drug Interaction Study to Assess the Effect of LY317615 on the Metabolic Pathway of Warfarin NCT01388335	Eli Lilly and Company	Phase 1
Completed	A Phase 1 Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies NCT00741871	S*BIO	Phase 1
Completed	Rituximab and Involved Field Radiotherapy in Early Stage Follicular Lymphoma NCT00509184	Klaus Herfarth, MD	Phase 2
Completed	Multi-day Doses in Prevention of Nausea and Emesis NCT00600353	University of Kansas Medical Center	Phase 2
Completed	Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies NCT00619879	Ann & Robert H Lurie Children's Hospital of Chicago	—
Completed	Dosing and Safety Study of E7820 in Patients With a Malignant Solid Tumor or Lymphoma NCT00078637	Eisai Inc.	Phase 1
Completed	Low-Intensity Preparation and Allogeneic Transplant in Patients With Cancers of the Blood NCT00146055	University of Michigan Rogel Cancer Center	Phase 2
Completed	Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia NCT00037791	Pfizer	Phase 3